UP-39 Infantile Bacillus Calmette-Guerin Vaccination and Bladder Cancer Incidence: Preliminary Analysis
Thursday June 27, 2019 from

Ahmed Kotb, Canada

Assistant Professor

Clinical Science

Northern Ontario School of Medicine


Infantile Bacillus Calmette-Guerin vaccination and bladder cancer incidence: Preliminary analysis

Sabrina Trigo1, Kaitlin Gonzalez1, Livio Di Matteo2, Asmaa Ismail1, Waleed Shabana1, Hazem Elmansy1, Walid Shahrour1, Owen Prowse1, Ahmed Kotb1.

1Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada; 2Economics, Lakehead University, Thunder Bay, ON, Canada

Introduction: The Bacillus Calmette-Guerin (BCG) vaccine has long been used for the prevention of tuberculosis (TB) around the world. BCG is also used as an immunotherapy agent for the treatment of non-musical invasive urinary bladder cancer. This preliminary analysis aims to analyse the available data for infantile BCG vaccination worldwide with the future development of bladder cancer.

Methods: Studies were identified by a formal literature search of MEDLINE and Cochrane Central. Preliminary data analysis was conducted on publicly accessible data summarizing the impact of gender, BCG vaccination, and socio-economic effects on crude and age-standardized rates of bladder cancer.

Results: As part of our analysis, preliminary regression models demonstrated BCG vaccination status, gender, and socio-economic status to have statistically significant effects on crude and age-standardized rates of bladder cancer incidence. BCG vaccination was associated with a 35-37% lower age-standardized rate of bladder cancer incidence.

Conclusion: There is very little literature examining the relationship between prior BCG vaccination and rates of bladder cancer incidence. Our limited data analysis indicates that a relationship does exist between infantile BCG vaccination and later bladder cancer development, although extensive future investigation is needed in this area.

© 2022 CUA 74th Annual Meeting